Hypophosphatemia Risk Associated With Intravenous Iron Therapies For Iron Deficiency Anemia

Home / Intelligence / Scientific Publications / Hypophosphatemia Risk Associated With Intravenous Iron Therapies For Iron Deficiency Anemia

The purpose of this study was to systematically assess rates of treatment-emergent hypophosphatemia among IDI formulations used in IDA.

Authors

Lim-Watson M, Libre M, Karkare S, Alkhateeb Z, Hadker N, Bajic-Lucas A, Dahl N, Strauss W, Glaspy J

Journal

ISPOR Meeting, May 2019

View publication

Related Intelligence

Scientific Publications

Treatment preferences among health care providers in the United States in selecting disease modifying therapies for multiple sclerosis: a discrete choice experiment study

Autoimmune screening panel (ASP) is routinely ordered as a part of diagnostic work-up in people with suspected multiple sclerosis (MS). However, data on prevalence and significance of ASP seropositivity in MS is scarce.

Scientific Publications

Burden of cremophor-related paclitaxel therapy on patients with ovarian cancer: A patient focused study from the United Kingdom, Germany, and Spain.

This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life implications.

Scientific Publications

Evaluating the Clinical, Economic, and Societal Value of Rapid Diagnostic Testing in Emerging Markets: A Systematic Literature Review Assessing Infectious Diseases

This study aimed to synthesize published and other literature on the clinical, societal, and economic value of RDTs for infectious disease across Asia, Africa, and Latin America.